

1 December 2020

ASX Announcement

Managing Director Share Sale – Mr Paul Brennan

Managing Director Mr Paul Brennan has sold 200,000 shares of which the proceeds will be put towards completing renovations of a residential property. Mr Brennan still holds 9,315,967 fully paid ordinary shares.

Mr Brennan joined the company as CEO in February 2015 and was then appointed Managing Director in April 2020. Mr Brennan remains a committed shareholder.

Further information.

Paul Brennan
Chief Executive Officer
Mobile, +61 427 662 317

David Williams
Chairman
Mobile +61 414 383 593

About NovoSorb®

NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and programmable bio-resorption profile.

About NovoSorb BTM

NovoSorb BTM is currently on sale in:

US, Australia, New Zealand, Australia, South Africa, India, Saudi Arabia, Israel and has regulatory approval for sale in Singapore and Malaysia. The CE Mark approval is expected with sales immediately following in UK, Ireland, Germany, Austria and Switzerland.

About PolyNovo®

PolyNovo is an Australian based medical device company that designs, develops and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information and market presentations see www.polynovo.com.au

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PolyNovo Limited
ABN	96 083 866 862

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Paul Brennan
Date of last notice	6 May 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	1 December 2020
No. of securities held prior to change	Across all holdings: 9,515,967 fully paid ordinary shares.
Class	Fully paid ordinary shares.
Number acquired	Nil
Number disposed	200,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$678,000.00 received by Paul Brennan for sale of 200,000 shares at \$3.39 per share via on market trade.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	Across all holdings: 9,315,967 fully paid ordinary shares.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Share sale via on market trade.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.